ASCO 2022 Conference Coverage

 

ASCO 2022 Conference Coverage
Avatar

ASCO 2022 on the Characteristics of Patients With Myelofibrosis on Ruxolitinib for Three or More Years

By ASCO 2022 Conference Coverage FEATURING Lucia Masarova
By ASCO 2022 Conference Coverage FEATURING Lucia Masarova
152 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

03:15
Lilly Medical Affairs

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Feat. W. Mchayleh

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy
MDS and MPN
08:09

ASCO 2022 on the Characteristics of Patients With Myelofibrosis on R…

ASCO 2022 Conference Coverage

L. Masarova

152 views
01:44

Lecture Summary - ASCO 2022 on the Characteristics of Patients With …

ASCO 2022 Conference Coverage

L. Masarova

13 views
14:33

ASCO 2022 Navitoclax + Ruxolitinib in JAKi-Naive Pts With MF: Prelim…

ASCO 2022 Conference Coverage

F. Passamonti

116 views
58

Lecture Summary - ASCO 2022 Navitoclax + Ruxolitinib in JAKi-Naive P…

ASCO 2022 Conference Coverage

F. Passamonti

16 views